TrialSignal transduction and targeted therapy2024

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.

Hongkai Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.